Delayed Nyse 04:00:24 2023-09-22 pm EDT |
|
5-day change | 1st Jan Change | |
151.58 USD | -0.37% | -1.23% | +0.01% |
Sep. 22 | HSBC Initiates Procter & Gamble With Buy Rating, Price Target is $179 | MT |
Sep. 14 | Johnson & Johnson, Procter & Gamble Sued in Florida Over Decongestant Cold Medicines | MT |
Financials (USD)
Sales 2024 * | 85,513 M | Sales 2025 * | 88,872 M | Capitalization | 357 B |
---|---|---|---|---|---|
Net income 2024 * | 15,690 M | Net income 2025 * | 16,710 M | EV / Sales 2024 * | 4,49x |
Net Debt 2024 * | 26,830 M | Net Debt 2025 * | 25,360 M | EV / Sales 2025 * | 4,31x |
P/E ratio 2024 * | 23,7x | P/E ratio 2025 * | 22,0x | Employees | - |
Yield 2024 * | 2,53% | Yield 2025 * | 2,64% | Free-Float | 58.80% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -0.37% | ||
1 week | -1.23% | ||
Current month | -1.79% | ||
1 month | -0.16% | ||
3 months | +1.09% | ||
6 months | +5.27% | ||
Current year | +0.01% |
1 week
151.38
154.78

1 month
151.38
155.32

Current year
135.83
158.38

1 year
122.18
158.38

3 years
121.54
165.35

5 years
78.49
165.35

10 years
65.02
165.35

Managers | Title | Age | Since |
---|---|---|---|
Jon Moeller
CEO | Chief Executive Officer | 59 | 2021 |
Andre Schulten
DFI | Director of Finance/CFO | 52 | 2021 |
Chief Tech/Sci/R&D Officer | - | 2020 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 54 | 2021 | |
Jon Moeller
CHM | Chairman | 59 | 2022 |
Director/Board Member | 57 | 2022 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.39% | 30 M$ | +7.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-22 | 151.58 | -0.37% | 6,328,163 |
23-09-21 | 152.14 | -0.87% | 5,098,146 |
23-09-20 | 153.47 | -0.08% | 5,446,571 |
23-09-19 | 153.60 | -0.29% | 4,704,209 |
23-09-18 | 154.05 | +0.38% | 3,536,490 |
Delayed Quote Nyse, September 22, 2023 at 04:00 pm EDT
More quotes
Procter & Gamble Company is one of the world's leaders in producing and selling consumer products. Net sales break down by family of products as follows:
- care and hygiene products (38.1%): oral hygiene products (toothpastes, toothbrushes, mouthwashes, etc.; Crest, Oral-B, Scope brands, etc.), pharmaceutical products (Metamucil, Neurobion, Pepto Bismol, Vicks, etc.), toilet training pants (Luvs, Pampers), toilet papers and paper towels (Bounty, Charmin, Puffs), feminine protection products (Always, Always Discreet and Tampax), etc.;
- home care and laundry products (34.4%): dishwashing liquids, detergents, stain removers, fabric softeners, deodorizers, bleaches, etc. (Ariel, Downy, Gain, Tide Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer, etc.);
- beauty products (18.3%): hair care products (shampoos, colorings, and cream rinses; Head & Shoulders, Herbal Essences, Pantene and Rejoice brands), body care (soaps, shower gels, deodorants, etc.; Camay, Zest, Secret, Old Spice) and cosmetics (make-up and facial care; Max Facto, Covergirl and Olay);
- shaving products (8.2%): blades, razors, batteries, etc. (Braun, Gillette and Venus brands);
- other (1%).
Export accounts for 54.5% of net sales.
Sector
Personal Products
Calendar
2023-10-10
- Annual General Meeting
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151.58USD
Average target price
167.01USD
Spread / Average Target
+10.18%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
+0.01% | 357 B $ | |
-1.48% | 127 B $ | |
-3.03% | 70 294 M $ | |
-8.05% | 59 894 M $ | |
-40.50% | 52 802 M $ | |
0.00% | 39 351 M $ | |
+17.49% | 30 443 M $ | |
+12.83% | 12 156 M $ | |
-0.03% | 11 988 M $ | |
+12.51% | 8 944 M $ |